$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
What kind of medicine is Rybrevant? Are there any side effects?
2025-10-19 11:44:20
Check Details
What does dacomitinib do? Are there any side effects?
2025-10-19 11:44:20
Check Details
Does the third-generation targeted drug for lung cancer, lorlatinib, have any side effects? What should we pay attention to
2025-10-19 11:44:20
Check Details
The FDA has approved the bispecific antibody Rybrevant for marketing. What are the efficacy and side effects of Rybrevant?
2025-10-19 11:44:20
Check Details
Does ramucirumab have serious side effects? What should we pay attention to?
2025-10-19 11:44:20
Check Details
Effects and side effects of Tepotinib Hydrochloride Tablets
2025-10-19 11:44:20
Check Details
Efficacy and side effects of serpatinib, a new drug for non-small cell lung cancer
2025-10-19 11:44:20
Check Details
What should I do if I have a bad appetite after taking gefitinib? What are the side effects of gefitinib?
2025-10-19 11:44:20
Check Details
What are the side effects of afatinib? How to deal with the side effects of afatinib?
2025-10-19 11:44:20
Check Details
What are the side effects of Lumakras, the world’s first KRAS targeted therapy? What's the price?
2025-10-19 11:44:20
Check Details
How long does it take for erlotinib rash to subside? How much does a box of erlotinib cost in Beijing?
2025-10-19 11:44:20
Check Details
Do you know the precautions and side effects of using serpatinib?
2025-10-19 11:44:20
Check Details
1
2
...
4099
4100
4101
4102
4103
4104
4105
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
2
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
3
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
4
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
5
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
6
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
7
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
8
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
9
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
10
Vemurafenib (Zelboraf) Complete Medication Guide
11
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
12
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer